865812-10-8

Basic information

• Product Name: (R)-O-TOLYL-CBS-OXAZABOROLIDINE, 0.5M I&
• Synonyms: (R)-O-TOLYL-CBS-OXAZABOROLIDINE, 0.5M I&;(r)-(+)-o-tolyl-cbs-oxazaborolidine solution;1H,3H-Pyrrolo[1,2-c][1,3,2]oxazaborole,tetrahydro-1-(2-Methylphenyl)-3,3-diphenyl-, (3aR)-
• CAS NO: 865812-10-8
• Molecular Formula: C24H24BNO
• Molecular Weight: 353.271
• Mol File: 865812-10-8.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 473.348ºC at 760 mmHg
• Flash Point: 4 °C
• Appearance: /
• Density: 0.900 g/mL at 25 °C
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: n20/D 1.514
• PKA: -0.32±0.40(Predicted)
• CAS DataBase Reference: (R)-O-TOLYL-CBS-OXAZABOROLIDINE, 0.5M I&(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-O-TOLYL-CBS-OXAZABOROLIDINE, 0.5M I&(865812-10-8)
• EPA Substance Registry System: (R)-O-TOLYL-CBS-OXAZABOROLIDINE, 0.5M I&(865812-10-8)

Safety Data

• Hazard Codes: F,Xn
• Statements: 11-38-48/20-63-65-67
• Safety Statements: 36/37-62-16
• RIDADR: UN 1294 3/PG 2
• WGK Germany: 3
• Hazardous Substances Data: 865812-10-8(Hazardous Substances Data)

Usage

Uses

(R)-(+)-o-Tolyl-CBS-oxazaborolidine is a chiral catalyst used in the organic reactions such as enantioselective diels-alder reactions.

InChI:InChI=1/C24H24BNO/c1-19-11-8-9-16-22(19)25-26-18-10-17-23(26)24(27-25,20-12-4-2-5-13-20)21-14-6-3-7-15-21/h2-9,11-16,23H,10,17-18H2,1H3/t23-/m1/s1

Upstream product

• 22348-32-9 (S)-diphenylprolinol 
• 7294-50-0 tri-o-tolylboroxine 
• 16419-60-6 2-Methylphenylboronic acid 
• 22348-32-9 (R)-α,α-diphenylprolinol 
• 156629-31-1 dibromo(o-tolyl)borane 

Relevant articles and documents

Enantioselective Strecker and Allylation Reactions with Aldimines Catalyzed by Chiral Oxazaborolidinium Ions

Chiral oxazaborolidinium ion (COBI)-catalyzed enantioselective nucleophilic addition reactions of aldimines using tributyltin cyanide and allyltributylstannane have been developed. Various α-aminonitriles and homoallylic amines were synthesized in high yi

HIV-1 PROTEASE INHIBITORS AND USES THEREOF

Various embodiments of the present invention are directed to compounds of the formula (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein X1, X2, X3, R1, R2, R11, and n are defined herein. These compounds are useful as inhibitors of HIV-1 protease and, as a result, are useful in the treatment of HIV infection.

SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE

Provided herein are formulations, processes, solid forms and methods of use relating to 2- (tert-butylamino)-4-((lR,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5- carboxamide.